Pevion's shareholders elect Jean-Paul Prieels, former Head Research GSK Vaccines, to its Board

Ittigen / Bern, Switzerland (ots) - Pevion Biotech AG today
announced that Jean-Paul Prieels has joined its Board of Directors.
Until January 2011, Dr. Prieels was Senior Vice President Research
and Development at GlaxoSmithKline Biologicals.

Jean-Paul Prieels joined GlaxoSmithKline Biologicals in 1987 as
Associate Director R&D Projects Evaluation. His responsibilities
gradually expanded to lead the global vaccine R&D development
activities in Rixensart, Belgium. His career spans from basic
research to process and product development. More specifically, he
was instrumental in developing several now commercially available
vaccines, such as rotavirus, human papilloma virus (HPV),
pneumococcal conjugates and others. Currently, Dr. Prieels is a Board
member of Immune Health and from 2000-2008 was a Board member of
Henogen. Since 2007 he is a member of the Scientific Advisory Board
of the Singapore Bioprocessing Technology Institute. He graduated
from the Free University of Brussels, Belgium, and holds a PhD in
Biochemistry.

"I am impressed by Pevion's virosome-based technology platform, as
well as, its team and potential. I eagerly look forward to
contributing my expertise in vaccine development", said Jean-Paul
Prieels following his election to the Board of Pevion.

"Due to his extensive scientific expertise and long track record,
Dr. Prieels is an ideal candidate to join Pevion and I am very
pleased that he has accepted a seat on the Board of Directors" said
Didier Hoch, Chairman of the Board.

"I warmly welcome Jean-Paul to our Board of Directors," said Evert
Kueppers, CEO of Pevion. "Dr Prieels has a long, distinguished career
in vaccine development, resulting in products that are now being used
throughout the world. He will give us important input, especially for
earlier portfolio decisions. Jean-Paul Prieels and Didier Hoch, who
was recently elected as Chairman and is a specialist for Pevion's
clinical stage Candida vaccine, will complement one another
perfectly".

About Pevion Biotech AG

Pevion Biotech AG is a fully independent Swiss vaccine company
that develops innovative vaccines for unmet medical needs based on
its clinically and commercially validated virosome technology. Its
proprietary clinical pipeline includes a first-in-class candidiasis
vaccine. A clinical stage malaria vaccine candidate has been
successfully out-licensed, and the Company's technology has been
licensed for use as an HIV vaccine currently in human trials. Pevion
has in-house development capability and expertise, including a state-
of-the-art and industrially scalable GMP manufacturing process.
Located near Bern, Pevion was established by its founding fathers,
Bachem AG (SWX: BANB) and Berna Biotech (now Crucell, a Johnson &
Johnson subsidiary). To date, Pevion has raised a total of CHF 45
million to date from its founders and investors, BZ Bank, CCP and BB
Biotech Ventures.

About Virosomes

Virosomes are the only regulatory and market-approved vaccine
technology to fulfill carrier and adjuvant functions in one.
Essentially, virosomes represent reconstituted empty influenza virus
envelopes, devoid of the genetic material of the source virus. As
such, virosomes do not replicate and are therefore an ideal
combination of carrier plus adjuvant for almost any given antigen,
including peptide or protein derived antigens. The technology allows
the surface display and delivery of difficult antigens and thereby
provides access to new indications and markets. Two virosome-based
vaccines (Epaxal® and Inflexal® V, marketed by Crucell Switzerland
AG) are licensed in over 40 countries, and more than 70 million doses
of these vaccines have been commercially distributed, thereby
providing a solid safety and efficacy track record.

Contact:
Evert Kueppers, CEO
Phone: +41/31/550'44'44
info@pevion.com

Pevion Biotech AG
Worblentalstrasse 32
CH - 3063 Ittigen
Switzerland

www.pevion.com